NCT03656133 2026-02-20Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal CancersH. Lee Moffitt Cancer Center and Research InstitutePhase NA Completed55 enrolled 10 charts
NCT05386550 2026-02-19Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)EMD SeronoPhase 3 Terminated166 enrolled 15 charts
NCT02586207 2025-10-07Pembrolizumab in Combination With CRT for LA-SCCHNSanford HealthPhase 1 Completed59 enrolled 9 charts
NCT06056310 2025-09-29Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)EMD SeronoPhase 1 Terminated18 enrolled 9 charts
NCT03529422 2025-07-20Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHNUNC Lineberger Comprehensive Cancer CenterPhase 2 Active not recruiting18 enrolled 10 charts
NCT03109873 2025-04-30Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck CancerThomas Jefferson UniversityPhase EARLY_PHASE1 Completed9 enrolled 6 charts